ACCD:NSD-Accolade Inc (USD)

COMMON STOCK | Health Information Services | NSD

Last Closing Price

USD 7.88

Change

-0.58 (-6.86)%

Market Cap

USD 0.57B

Volume

1.63M

Avg Analyst Target

USD 19.30 (+144.92%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ACCD Stock Forecast & Price:
Based on the Accolade Inc stock forecasts from 13 analysts, the average analyst target price for Accolade Inc is USD 19.30 over the next 12 months. Accolade Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Accolade Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Accolade Inc’s stock price was USD 7.88. Accolade Inc’s stock price has changed by +31.33% over the past week, +21.79% over the past month and -85.67% over the last year.

About Accolade Inc (ACCD:NSD)

Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technol ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-06-28 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CERN Cerner Corp

N/A

USD27.92B 48.06 18.97
CHNG Change Healthcare Inc

-0.28 (-1.18%)

USD7.54B N/A 14.48
INOV Inovalon Holdings Inc

N/A

USD6.37B 122.57 33.93
RCM R1 RCM Inc

-0.80 (-3.63%)

USD6.06B 61.56 28.60
HQY Healthequity Inc

-1.63 (-2.44%)

USD5.64B 789.30 61.10
TXG 10X Genomics Inc

-2.07 (-4.23%)

USD5.63B N/A N/A
OMCL Omnicell Inc

-3.98 (-3.21%)

USD5.38B 81.78 32.12
PINC Premier Inc

-0.89 (-2.39%)

USD4.39B 15.87 9.67
CERT Certara Inc

-0.25 (-1.13%)

USD3.60B N/A 50.44
HMSY HMS Holdings Corp

N/A

USD3.29B 47.40 23.59

ETFs Containing ACCD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -70.11% 17% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.11% 17% F 12% F
Trailing 12 Months  
Capital Gain -85.67% 15% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.67% 15% F 10% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -20.98% 9% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.98% 9% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 32.33% 62% D- 51% F
Risk Adjusted Return -64.89% 15% F 8% F
Market Capitalization 0.57B 53% F 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 100% A+ 97% A+
Price/Book Ratio 0.47 94% A 94% A
Price / Cash Flow Ratio -9.13 81% B- 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -19.75% 29% F 36% F
Return on Invested Capital -15.72% 29% F 34% F
Return on Assets -11.21% 30% F 30% F
Debt to Equity Ratio 32.80% 55% F 50% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.57 83% B 70% C-
Short Percent 6.38% 33% F 29% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.